Kalaris Therapeutics
KLRS
76 hedge funds and large institutions have $36.4M invested in Kalaris Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 28 reducing their positions, and 17 closing their positions.
19,950% more call options, than puts
Call options by funds: $401K | Put options by funds: $2K
26% more capital invested
Capital invested by funds: $28.8M → $36.4M (+$7.58M)
0.26% more ownership
Funds ownership: 1.62% → 1.88% (+0.26%)
6% less funds holding
Funds holding: 81 → 76 (-5)
25% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 28
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.01M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$2.98M |
| 3 |
ICM
Irenic Capital Management
New York
|
+$1.83M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$984K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
+$695K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.85M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.57M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$1.71M |
| 4 |
Millennium Management
New York
|
-$682K |
| 5 |
Morgan Stanley
New York
|
-$476K |
KLRS Hedge Fund Activity: Q1 2024 in Review
76 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2024, worth a combined $36.4M — up 26% from $28.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KLRS and 12 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 21 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $8.01M. The largest seller was Fidelity Investments, cutting an estimated $3.85M.
- 76 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2024, down from 81 in Q4 2023.
- Funds reported $36.4M of Kalaris Therapeutics stock for Q1 2024, up 26% quarter-over-quarter.
- 12 funds opened new Kalaris Therapeutics positions in Q1 2024 and 17 closed out, a net change of -5 holders.
- The largest Kalaris Therapeutics buyer in Q1 2024 was EcoR1 Capital, an estimated $8.01M added.
- The largest Kalaris Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $3.85M sold.
Based on aggregated 13F filings for Q1 2024.